利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

54 条记录 (耗时 0.058 秒)

    Chimeric chains for receptor-associated signal transduction pathways
    1.
    发明授权
    Chimeric chains for receptor-associated signal transduction pathways 失效
    用于受体相关信号转导途径的嵌合链

    公开(公告)号：US06319494B1

    公开(公告)日：2001-11-20

    申请号：US08479737

    申请日：1995-06-07

    申请人： Daniel J. Capon ,  Arthur Weiss ,  Brian A. Irving ,  Margo R. Roberts ,  Krisztina Zsebo

    发明人： Daniel J. Capon ,  Arthur Weiss ,  Brian A. Irving ,  Margo R. Roberts ,  Krisztina Zsebo

    IPC分类号： C12N1500

    CPC分类号： C07K14/70514 ,  C07K14/7051 ,  C07K14/70535 ,  C07K2319/00

    摘要： Chimeric proteins and DNA encoding chimeric proteins are provided, where the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner, a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. The extracellular domain and cytoplasmic domain are not naturally found together. Binding of ligand to the extracellular domain results in transduction of a signal and activation of a signaling pathway in the cell, whereby the cell may be induced to carry out various functions relating to the signalling pathway. A wide variety of extracellular domains may be employed as receptors, where such domains may be naturally occurring or synthetic. The chimeric DNA may be used to modify lymphocytes as well as hematopoietic stem cells as precursors to a number of important cell types.

    摘要翻译： 提供嵌合蛋白和编码嵌合蛋白的DNA，其中嵌合蛋白的特征在于能够以非MHC限制性方式结合配体的细胞外结构域，能够激活信号通路的跨膜结构域和胞质结构域。 细胞外结构域和细胞质结构域不是天生地共同发现的。 配体与细胞外结构域的结合导致信号的转导和信号通路在细胞中的激活，由此可诱导细胞进行与信号通路相关的各种功能。 可以使用多种细胞外结构域作为受体，其中这些结构域可以是天然存在的或合成的。 嵌合DNA可用于修饰淋巴细胞以及造血干细胞作为许多重要细胞类型的前体。

    Chimeric chains for receptor-associated signal transduction pathways
    2.
    发明授权
    Chimeric chains for receptor-associated signal transduction pathways 失效
    用于受体相关信号转导途径的嵌合链

    公开(公告)号：US06407221B1

    公开(公告)日：2002-06-18

    申请号：US08475442

    申请日：1995-06-07

    申请人： Daniel J. Capon ,  Arthur Weiss ,  Brian A. Irving ,  Margo R. Roberts ,  Krisztina Zsebo

    发明人： Daniel J. Capon ,  Arthur Weiss ,  Brian A. Irving ,  Margo R. Roberts ,  Krisztina Zsebo

    IPC分类号： C07H2104

    CPC分类号： C07K14/70514 ,  C07K14/7051 ,  C07K14/70535 ,  C07K2319/00

    摘要： Chimeric proteins and DNA encoding chimeric proteins are provided, where the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner, a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. The extracellular domain and cytoplasmic domain are not naturally found together. Binding of ligand to the extracellular domain results in transduction of a signal and activation of a signaling pathway in the cell, whereby the cell may be induced to carry out various functions relating to the signalling pathway. A wide variety of extracellular domains may be employed as receptors, where such domains may be naturally occurring or synthetic. The chimeric DNA may be used to modify lymphocytes as well as hematopoietic stem cells as precursors to a number of important cell types.

    摘要翻译： 提供嵌合蛋白和编码嵌合蛋白的DNA，其中嵌合蛋白的特征在于能够以非MHC限制性方式结合配体的细胞外结构域，能够激活信号通路的跨膜结构域和胞质结构域。 细胞外结构域和细胞质结构域不是天生地共同发现的。 配体与细胞外结构域的结合导致信号的转导和信号通路在细胞中的激活，由此可诱导细胞进行与信号通路相关的各种功能。 可以使用多种细胞外结构域作为受体，其中这些结构域可以是天然存在的或合成的。 嵌合DNA可用于修饰淋巴细胞以及造血干细胞作为许多重要细胞类型的前体。

    Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
    4.
    发明授权
    Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening 有权
    用于确定抗病毒药物敏感性和耐药性以及抗病毒药物筛选的组合物和方法

    公开(公告)号：US07279279B2

    公开(公告)日：2007-10-09

    申请号：US10846181

    申请日：2004-05-14

    申请人： Daniel J. Capon ,  Christos J. Petropoulos

    发明人： Daniel J. Capon ,  Christos J. Petropoulos

    IPC分类号： C12Q1/68

    CPC分类号： C12N15/86 ,  C12N2740/16043 ,  C12N2830/00 ,  C12N2830/15 ,  C12N2830/60 ,  C12N2840/20 ,  C12N2840/203 ,  C12N2840/206 ,  C12N2840/44 ,  C12Q1/18 ,  C12Q1/6881 ,  C12Q1/6897 ,  C12Q1/701 ,  C12Q1/703 ,  C12Q1/707 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N2333/16 ,  G01N2800/52 ,  C12Q2545/113

    摘要： This invention provides a method for determining susceptibility for an anti-viral drug comprising: (a) introducing a resistance test vector Comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell; and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-viral drug, wherein a test concentration of the anti-viral drug is present at steps (a)-(c); at steps (b)-(c); or at step (c). This invention also provides a method for determining anti-viral drug resistance in a patient comprising: (a) determining anti-viral drug susceptibility in the patient at a first time using the susceptibility test described above, wherein the patient-derived segment is obtained from the patient at about said time; (b) determining anti-viral drug susceptibility of the same patient at a later time; and (c) comparing the anti-viral drug susceptibilities determined in step (a) and (b), wherein a decrease in anti-viral drug susceptibility at the later time compared to the first time indicates development or progression of anti-viral drug resistance in the patient.

    摘要翻译： 本发明提供了一种用于确定抗病毒药物的易感性的方法，包括：（a）将包含患者来源区段和指示基因的抗性测试载体导入宿主细胞; （b）从（a）培养宿主细胞; （c）测量靶宿主细胞中指示基因的表达; 和（d）比较来自（c）的指示基因的表达与在不存在抗病毒药物的情况下进行步骤（a） - （c）时测量的指示基因的表达，其中测试浓度 在步骤（a） - （c）中存在抗病毒药物; 在步骤（b） - （c）; 或在步骤（c）。 本发明还提供了一种用于测定患者抗病毒药物耐药性的方法，包括：（a）使用上述敏感性试验在第一时间确定患者的抗病毒药物敏感性，其中所述患者衍生部分获自 病人约在上述时间; （b）以后确定同一病人的抗病毒药物敏感性; 和（c）比较步骤（a）和（b）中确定的抗病毒药物敏感性，其中与第一次相比后来的抗病毒药物敏感性的降低表明抗病毒药物耐药性的发展或进展 在病人身上

    HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE
    10.
    发明申请
    HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE 审中-公开
    含有非肽链的杂交免疫抑制剂

    公开(公告)号：US20170008950A1

    公开(公告)日：2017-01-12

    申请号：US15125774

    申请日：2015-03-13

    申请人： Daniel J. Capon

    发明人： Daniel J. Capon

    IPC分类号： C07K16/00 ,  A61K47/48 ,  C07K16/24 ,  C07K16/46

    CPC分类号： C07K16/00 ,  A61K47/6801 ,  A61K47/6855 ,  A61K47/6875 ,  A61K47/6889 ,  C07K16/241 ,  C07K16/46 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/76

    摘要： The present invention provides a compound having the structure: A-B-----Z wherein A is a biologically active structure of the compound; wherein Z is a protein component of the compound, which protein component comprises one or more polypeptides, wherein at least one of the one or more polypeptides comprises consecutive amino acids which (i) are identical to a stretch of consecutive amino acids present in a chain of an Fc domain of an antibody; (ii) bind to an Fc receptor; and (iii) have at their N-terminus a sequence selected from the group consisting of a cysteine or selenocysteine; wherein the dashed line between B and Z represents a peptidyl linkage; and wherein the solid line between A and B represents a nonpeptidyl linkage, as well as intermediates dimers thereof, and processes of producing the compounds of the invention.

    摘要翻译： 其中A是化合物的生物活性结构; 其中Z是所述化合物的蛋白质组分，所述蛋白质组分包含一种或多种多肽，其中所述一种或多种多肽中的至少一种包含连续氨基酸，其（i）与存在于链中的连续氨基酸序列相同 的抗体的Fc结构域; （ii）结合Fc受体; 和（iii）在其N-末端具有选自半胱氨酸或硒代半胱氨酸的序列; 其中B和Z之间的虚线表示肽基键; 并且其中A和B之间的实线表示非肽基键，以及其中间体二聚体，以及制备本发明化合物的方法。